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Eleven new acylphloroglucinols, including seven new formylated phloroglucinol-monoterpene 
meroterpenoids, eucalyprobusals A–F (1–6), one monomeric acylphloroglucinol, 
eucalyprobusone B (7), and four dimeric acylphloroglucinols, eucalyprobusones C–F (8–11) 
were purified from the fruits of Eucalyptus robusta. The establishment of the structures of 1–
11 was achieved by a combination of NMR and HRESIMS data analyses, electron circular 
dichroism (ECD), and single-crystal X-ray diffraction. Compounds 6, 8, and an inseparable 
mixture of 10 and 11 were found to be potent AChE inhibitors with IC50 values of 3.22 ± 0.36, 
3.82 ± 0.22, and 2.55 ± 0.28 μΜ, respectively. Possible interaction sites of 6, 8, 10, and 11 with 
AChE were investigated by means of molecular docking studies, and the results revealed that 
AChE residues Asn87, Ser125, Thr83, Tyr133, Tyr124, Tyr337, and Tyr341 played crucial 
roles in the observed activity of the aforementioned compounds. 
 





Plants of Eucalyptus genus (Myrtaceae) are a prolific resource of phloroglucinol derivatives, 
especially formylated phloroglucinol meroterpenoids (FPMs) [1–4]. These Eucalyptus secondary 
metabolites not only possess multifarious bioactive properties, including protein tyrosine 
phosphatase 1B inhibitory [2], immunosuppressive [3], antimicrobial [4,5], antiviral [6], 
anticancer [7–9], AChE inhibitory [10], and anti-leishmanial [11] effects, but also have attracted 
significant attention from the synthetic organic chemistry community [12–18]. Eucalyptus 
robusta, a tall arbor indigenous to Australia, is widely cultivated in south China. Its leaves have 
been traditionally used as a Chinese folk medicine to treat dysentery, malaria, and bacterial 
diseases [19], whereas its fruits are usually used for the main treatment of malaria. 
Alzheimer’s disease (AD), a neurodegenerative disorder associated with memory and other 
cognitive functions, has been commonly known as one of the most burdensome threats to 
increasingly elderly people [20,21]. Currently, the causative factors of AD are not fully 
understood, pathophysiological brain hallmarks mainly include low levels of acetylcholine (ACh), 
amyloid-β (Aβ) deposits, and neurofibrillary tangles. Despite decades of study for the basic 
biology of AD and significant pharmaceutical efforts to develop viable therapies, there is no 
effective therapy to totally cure AD or to significantly inhibit the progression of AD symptoms. 
Pharmacologically, three marketed acetylcholinesterase inhibitors (AChEIs) that are approved by 
U.S. FDA, named donepezil, rivastigmine, and galantamine [22], are only relevant medicines 
available for the treatment of ameliorating the symptoms of AD patients. All these AChEIs acting 
on central nervous system (CNS) cholinergic pathways are now approved for mild to severe 
dementia, although they are widely used for patients in earlier predementia stages associated with 
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significant progressive memory impairment. Therefore, it would be of great significance to hunt 
for potent AChEIs from medicinal plant resources. The PE (petroleum ether)–EtOAc (ethyl 
acetate) extract of E. robusta fruits displayed an AChE inhibitory rate of 68% at the concentration 
of 500 μg/mL, which prompted further phytochemical investigation with the aim at clarifying its 
bioactive constituents. As a result, five new FPMs, eucalyprobusals A–F (1–6), one monomeric 
acylphloroglucinol, eucalyprobusone B (7), and four acylphloroglucinol dimers, eucalyprobusones 
B–F (8–11) were isolated and structurally characterized (Fig. 1). AChE inhibitory assays of 1–11 
were performed, and the possible action sites of 6, 8, 10, and 11 with AChE were also 
accomplished via molecular docking methods. 
 




2.1. General experimental procedures 
Optical rotation and UV spectra were measured on a AUTOPOL VI automatic and a 
SHIMADZU UV-2700 UV-VIS instruments, respectively. CD data were recorded on an Applied 
Photophysics spectropolarimeter. A Bruker FT-IR Tensor-27 infrared spectrophotometer was 
utilized for measuring the IR spectra (KBr disks). NMR spectra were collected on Bruker Ascend 
500, 600, and 800 MHz instruments with various solvent (including CDCl3, methanol-d4, acetone-
d6, and pyridine-d5) signals as referenced internal standards. An Agilent 1290 UPLC/6540 Q-TOF 
system was used for HRESIMS data. Crystallographic data of 1 and a mixture of 10 and 11 were 
obtained using a Bruker D8 QUEST diffractometer (λ = 1.54178 Å) with Cu Kα radiation. Silica 
gel, Sephadex LH-20, and MCI were applied as the packing materials for CC (column 
chromatography). Chiral analysis was performed on an Agilent 1100 instrument with a 
CHIRALPAK IC column (4.6 × 250 mm, 5 μm). A Hanbon Newstyle preparative HPLC 
instrument equipped with a SunFire Prep C18 column (10 × 250 mm, 5 μm) was used to purify 
compounds. A Bruker APEX DUO diffractometer was chosen to acquire X-ray diffraction data. 
2.2. Plant material 
The E. robusta fruits authenticated by Dr. Rong Li (Kunming Institute of Botany, CAS) were 
collected from Kunming, Yunnan province, People’s Republic of China. A voucher specimen 
(HY0032) is deposited in the State Key Laboratory of Phytochemistry and Plant Resources in West 
China, Kunming Institute of Botany, Chinese Academy of Sciences. 
2.3. Extraction and isolation 
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The dried E. robusta fruits (5.0 kg) were powdered and extracted with PE–EtOAc (1:1 v/v, 15  
L × 3, each 24 h) to afford an inquinate residue. This crude extract (230.0 g) was subjected to silica 
gel CC eluting with PE–EtOAc (100:1→1:1, v/v) to afford six fractions (Fr. A–Fr. F) as monitored 
based on TLC by spraying with 10% FeCl3-EtOH. Fr. D (20.5 g) was separated on an RP-18 
column (MeOH–H2O, 60:40→100:1, v/v, 1‰ FA in H2O) and was further purified with a 
Sephadex LH-20 column (MeOH) and semipreparative HPLC (MeCN–H2O, 80:20 v/v, 1‰ FA in 
H2O) to yield 7 (22.2 mg), 8 (10.2 mg), 9 (6.8 mg), and a mixture of 10 and 11 (31.1 mg). Fr. E 
(10.5 g) was fractionated by an RP-18 column (MeOH–H2O, 50:50→100:1, v/v, 1‰ FA in H2O) 
and further purified via semipreparative HPLC (MeOH–H2O, 98:2 v/v, 1‰ FA in H2O) to give 4 
(2.4 mg), 5 (3.3 mg), and 6 (54.3 mg). Likewise, Fr. F (16.0 g) was separated on an RP-18 column 
(MeOH–H2O, 50:50→100:1, v/v, 1‰ FA in H2O) and followed by semipreparative HPLC 
(MeCN–H2O, 90:10 v/v, 1‰ FA in H2O) to afford 1 (12.1 mg), 2 (8.8 mg), and 3 (1.4 mg). 
2.3.1. Eucalyprobusal A (1) 
Yellowish crystals (methanol-acetone, 1:1 v/v); [α]
23
D +91.8 (c 0.11, MeOH); UV (MeOH) 
λmax (log ε) 207 (4.26), 281 (4.47), 368 (3.57) nm; IR (KBr) νmax 3440, 2954, 1641, 1180, 781 
cm−1; 1H (500 MHz, CDCl3) and 
13C (125 MHz, CDCl3) NMR spectral data, see Table 1; (+)-
HRESIMS m/z 425.1939 [M + Na]+ (calcd for C23H30O6Na, 425.1935). 
2.3.2. Eucalyprobusal B (2) 
Yellowish amorphous powder; [α]
24
D –31.4 (c 0.12, MeOH); UV (MeOH) λmax (log ε) 206 
(4.22), 281.5 (4.38), 373 (3.55) nm; ECD (MeOH, Δε) 204 (+3.53), 213 (+1.20), 226 (+3.73), 246 
(+0.42), 274 (+10.22), 306 (−6.48) nm; IR (KBr) νmax 3441, 2952, 1641, 1179, 780 cm
−1; 1H (500 
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MHz, CDCl3) and 
13C (125 MHz, CDCl3) NMR spectral data, see Table 1; (+)-HRESIMS m/z 
425.1942 [M + Na]+ (calcd for C23H30O6Na, 425.1935). 
2.3.3. Eucalyprobusal C (3) 
Yellowish amorphous powder; [α]
24
D –254.3 (c 0.12, MeOH); UV (MeOH) λmax (log ε) 206 
(4.28), 273 (4.38), 343 (3.71), 380 (3.53) nm; ECD (MeOH, Δε) 221 +27.39), 267 (−1.44), 290 
(+2.04), 343 (−4.56) nm; IR (KBr) νmax 3439, 2943, 1632, 1430, 1057 cm
−1; 1H (800 MHz, CDCl3) 
and 13C (200 MHz, CDCl3) NMR spectral data, see Table 1; (–)-HRESIMS m/z 401.1978 [M – 
H]– (calcd for C23H29O6, 401.1970). 
2.3.4. Eucalyprobusal D (4) 
Yellowish amorphous powder; [α]
25
D –307.3 (c 0.13, MeOH); UV (MeOH) λmax (log ε) 206 
(3.15), 236 (3.09), 279 (3.23) nm; ECD (MeOH, Δε) 206 (−5.91), 242 (+9.73), 269 (−20.5), 316 
(−0.59), 343 (−3.69) nm; IR (KBr) νmax 3436, 2937, 1721, 1629, 1468, 1024 cm−1; 1H (500 MHz, 
CDCl3) and 
13C (125 MHz, CDCl3) NMR spectral data, see Table 1; (+)-HRESIMS m/z 423.1772 
[M + Na]+ (calcd for C23H28O6Na, 423.1778). 
2.3.5. Eucalyprobusal E (5) 
Yellowish amorphous powder; [α]
25
D –53.7 (c 0.09, MeOH); UV (MeOH) λmax (log ε) 206 
(4.00), 276 (4.09), 335 (3.39), 366 (3.20) nm; ECD (MeOH, Δε) 215 (+2.07), 239 (−0.61), 263 
(+1.27), 292 (–0.58), 354 (+0.03) nm; 1H (500 MHz, methanol-d4) and 
13C (125 MHz, methanol-
d4) NMR spectral data, see Table 1; (+)-HRESIMS m/z 397.1051 [M + K]
+ (calcd for C20H22O6K, 
397.1048). 





D +86.8 (c 0.10, MeOH) for (+)-6; [α]
22
D –86.2 (c 0.10, MeOH) for (–)-6; 
UV (MeOH) λmax (log ε) 202 (4.38), 213 (4.37), 291 (4.27), 388 (3.76) nm; ECD (MeOH, Δε) 204 
(+14.46), 227 (+1.06), 246 (+21.48), 264 (+1.75), 274 (+3.08), 322 (–0.21) nm for (+)-6; ECD 
(MeOH, Δε) 204 (–13.89), 227 (–1.03), 246 (–20.39), 264 (–1.68), 274 (–2.97), 322 (+0.20) for (–
)-6; 1H (methanol-d4, 500 MHz) NMR δ 0.88 (3H, d, J = 6.6 Hz, H3-13'), 0.94 (3H, d, J = 6.6 Hz, 
H3-12'), 1.17 × 2 (6H, d, J = 7.0 Hz, H3-8/H3-9), 1.49 (1H, m, H-11'), 1.80 (1H, ddd, J = 14.5, 8.0, 
6.6 Hz, H-10'b), 2.19 (1H, ddd, J = 14.5, 8.4, 5.2 Hz, H-10'a), 2.22 (3H, s, H3-10), 2.78 (1H, sept., 
J = 7.0 Hz, H-7), 4.65 (1H, dd, J = 9.6, 6.6 Hz, H-9'), 6.85 (1H, dd, J = 7.8, 1.5 Hz, H-4), 6.91 
(1H, d, J = 7.8 Hz, H-5), 7.45 (1H, d, J = 1.5 Hz, H-2), 10.05 (2H, s, H-7'/H-8'); 13C (methanol-
d4,125 MHz) NMR δ 19.5 (C-10), 22.9 (C-12'), 23.8 (C-13'), 24.6 (C-8), 24.7 (C-9), 27.4 (C-11'), 
35.0 (C-9'), 35.2 (C-7), 42.9 (C-10'), 106.3 × 2 (C-2'/C-4'), 111.3 (C-6'), 124.6 (C-4), 127.7 (C-2), 
131.0 (C-5), 134.7 (C-6), 142.9 (C-1), 146.8 (C-3), 169.1 (C-3'), 169.9 × 2 (C-1'/C-5'), 193.1 × 2 
(C-7'/C-8'); (–)-HRESIMS m/z 383.1872 [M – H]– (calcd for C23H27O5, 383.1864). 
2.3.7. Eucalyprobusone B (7) 
Yellowish gum; UV (MeOH) λmax (log ε) 205 (3.87), 272 (4.22), 321 (3.59) nm; 
1H NMR 
(CDCl3, 500 MHz) δ 1.16 × 2 (6H, d, J = 6.8 Hz, H3-10/H3-11), 3.68 (1H, sept., J = 6.8 Hz, H-9), 
3.95 (3H, s, OCH3-3), 5.91 (1H, s, H-4), 10.20 (1H, s, H-8), 12.99 (1H, s, OH-5), 15.50 (1H, s, 
OH-1); 13C NMR (CDCl3, 125 MHz) δ 19.1 × 2 (C-10/C-11), 39.6 (C-9), 56.2 (OCH3-3), 90.8 (C-
4), 103.4 (C-2), 105.3 (C-6), 168.1 (C-3), 169.9 (C-5), 171.8 (C-1), 192.7 (C-8), 210.5 (C-7); (+)-
HRESIMS m/z 261.0735 [M + Na]+ (calcd for C12H14O5Na, 261.0733). 





D +72.5 (c 0.10, MeOH) for (+)-8; [α]
22
D –72.4 (c 0.10, MeOH) for (–)-8; 
UV (MeOH) λmax (log ε) 207 (4.48), 302 (4.43) nm; ECD (MeOH, Δε) 213 (–3.46), 234 (+13.65), 
264 (–0.15), 308 (+4.11) nm for (+)-8; ECD (MeOH, Δε) 213 (+3.40), 235 (–13.39), 264 (+0.15), 
308 (–4.04) for (–)-8; 1H (600 MHz, acetone-d6) and 
13C (150 MHz, acetone-d6) NMR spectral 
data, see Table 2; (+)-HRESIMS m/z 503.2645 [M + H]+ (calcd for C28H39O8, 503.2639). 
2.3.9. Eucalyprobusone D (9) 
Yellowish gum; UV (MeOH) λmax (log ε) 234 (4.42), 301 (3.44) nm; 
1H (600 MHz, CDCl3) 
and 13C (150 MHz, CDCl3) NMR spectral data, see Table 2; (–)-HRESIMS m/z 499.1345 [M + 
K]+ (calcd for C24H28O9K, 499.1365). 
2.3.10. (±)-Eucalyprobusones E (10) and F (11) 
Colorless crystals (methanol-acetone, 1:1 v/v); [α]
23
D –0.67 (c 0.15, MeOH); UV (MeOH) λmax 
(log ε) 207 (4.43), 302 (4.38) nm; 1H (600 MHz, pyridine-d5) and 
13C (150 MHz, pyridine-d5) 
NMR spectral data, see Table 3; (+)-HRESIMS m/z 525.2467 [M + Na]+ (calcd for C28H38O8Na, 
525.2459). 
2.3.11. Crystallographic data for eucalyprobusal A (1) 
C23H30O6, M = 402.47, a = 10.3730(6) Å, b = 13.0331(8) Å, c = 31.5028(18) Å, α = 90°, β = 
90°, γ = 90°, V = 4258.9(4) Å3, T = 100.(2) K, wavelength 1.54178 Å, orthorhombic crystal system, 
space group P212121, Z = 8, absorption coefficient 0.735 mm
–1, μ(Cu Kα) = 0.735 mm–1, F(000) = 
1728, crystal size 0.260 × 0.200 × 0.140 mm3, θ range for data collection 3.67 to 72.32°, index 
ranges –12 ≤ h ≤ 12, –13 ≤ k ≤ 16, –38 ≤ l ≤ 38, 35845 reflections collected, 8336 independent 
reflections (Rint = 0.0249), completeness to θ (72.32°) 99.4%, data/restraints/parameters 
8336/0/553, largest diff. peak and hole 0.205 and –0.154 e.Å–3. The final R1 values were 0.0247 
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[I > 2σ(I)]. The final wR(F2) values were 0.0647 [I > 2σ(I)]. The final R1 values were 0.0250 (all 
data). The final wR(F2) values were 0.0649 (all data). The goodness of fit on F2 was 1.042. Flack 
parameter = –0.01(2). Crystallographic data for 1 is deposited at CCDC (Cambridge 
Crystallographic Data Center) with a number of CCDC 2003650. 
2.3.12. Crystallographic data for (±)-eucalyprobusones E (10) and F (11) 
C28H38O8, M = 502.58, a = 11.2889(2) Å, b = 11.5007(2) Å, c = 11.7348(2) Å, α = 
81.6690(10)°, β = 78.5010(10)°, γ = 63.8270(10)°, V = 1337.06(4) Å3, T = 100.(2) K, wavelength 
1.54178 Å, triclinic crystal system, space group P-1, Z = 2, absorption coefficient 0.744 mm–1, 
μ(Cu Kα) = 0.744 mm–1, F(000) = 540, crystal size 0.630 × 0.480 × 0.270 mm3, θ range for data 
collection 4.29 to 72.38°, index ranges –13 ≤ h ≤ 13, –14 ≤ k ≤14, –14 ≤ l ≤ 14, 42727 reflections 
measured, 5244 independent reflections (Rint = 0.0421) completeness to θ (72.38°) 99.3%, 
data/restraints/parameters 5244/255/425, largest diff. peak and hole 1.093 and –0.430 e.Å–3. The 
final R1 values were 0.0707 [I > 2σ(I)]. The final wR(F
2) values were 0.1933 [I > 2σ(I)]. The final 
R1 values were 0.0712 (all data). The final wR(F
2) values were 0.1936 (all data). The goodness of 
fit on F2 was 1.111. Crystallographic data for 10 and 11 is deposited at CCDC (Cambridge 
Crystallographic Data Center) with a number of CCDC 2003659. 
2.4. ECD computational methods 
The ECD calculations of 2–6 and 8 were carried out using Gaussian 16 [23]. Conformational 
analysis of 2–6 and 8 was carried out by CONFLEX 8B software (CONFLEX Corporation, Tokyo, 
Japan) using MMFF94s molecular force field with a search limit of 1.0 kcal/mol to yield six, six, 
three, four, two, and 10 conformers, respectively. These initial structures were optimized via the 
Density Functional Theory (DFT) at the B3LYP/6-31 + G(d) level in gas phase. The optimized 
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conformations were used for ECD calculations by the Time Dependent DFT (TDDFT) at the 
B3LYP/6-311++G (2d, p) level. 
2.5. AChE inhibitory assay 
AChE inhibitory effects of all the isolated phloroglucinols were carried out on the basis of 
the spectrophotometric method in 96-well microplates with slightly modification [24]. Each well 
was filled with human acetylcholinesterase (0.02 U/mL, Sigma-Aldrich Corp., USA), phosphate 
buffer (pH = 8.0), and tested phloroglucinols (100, 50.0, 30.0, 10.0, 3.0, 1.0, and 0.2 μM) in DMSO 
and then incubated for 20 min at 37°C. These reactions were initiated by the addition of 40 μL of 
solution containing Ellman’s reagent (DTNB, 0.625 mM of 5,5'-dithiobis-2-nitrobenzoic acid) and 
acetylthiocholine iodide (0.625 mM) for AChE inhibitory assays, respectively. The results of 
acetylthiocholine hydrolysis were monitored at 405 nm for 1.0 h (30 s interval readings). DMSO 
and galanthamine were selected as the negative and positive controls, respectively. The percentage 
inhibition was calculated as follows:  
𝑖𝑛ℎ𝑖𝑏𝑖𝑡𝑖𝑜𝑛 (%) =
E −  S
E
× 100 
(E and S are the average absorption values for the enzyme activities treated without and with 
tested compounds, respectively). 
2.3.6. Molecular modeling  
Discovery Studio was used to carry out molecular docking studies using recently published 
methods [25]. 
 
3. Results and discussion 
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3.1. Structural elucidation 
Dried and powdered fruits of E. robusta were extracted four times by PE‒EtOAc at room 
temperature. The obtained extract was separated using silica gel chromatrography to give six 
fractions (Fr. A−Fr. F). Fractions D, E, and F were repeatedly chromatographed on silica gel, 
Sephadex LH-20, and RP-18 columns as well as using semipreparative HPLC to yield 11 new 
acylphloroglucinols (1‒11). The structures of 1‒11 were elucidated employing a combination of 
NMR and HRMS data analyses; the absolute configurations of 1‒6 and 8 were established based 
on X-ray diffraction or ECD calculations. 1‒6 are phloroglucinol‒monoterpene conjugates, 
whereas 7 and 8‒11 are mono- and dimeric-acylphloroglucinols (Fig. 1), respectively. Among 
them, 10 and 11 were found to be an inseparable mixture of two pairs of enantiomers. 
Eucalyprobusal A (1), a yellowish crystal, had a molecular formula of C23H30O6 as 
determined by the observed sodium adduct ion at m/z 425.1939 [M + Na]+ (calcd for C23H30O6Na, 
425.1935) in the HRESIMS spectrum. The IR spectrum showed absorptions at 3440 and 1641 
cm−1 which indicated the existence of hydroxy and carbonyl functionalities, respectively. The 1H 
NMR spectral data (Table 1) disclosed resonances for four secondary methyls (δH 0.87, d, J = 6.8 
Hz, H3-10; 0.93, d, J = 6.8 Hz, H3-9; 0.96, d, J = 6.5 Hz, H3-13'; 1.00, d, J = 6.5 Hz, H3-125'), a 
tertiary methyl (δH 1.39, s, H3-7), two olefinic protons (δH 5.83, dd, J = 9.8, 1.0 Hz, H-3; 5.88, d, 
J = 9.8 Hz, H-2), two aldehyde protons (δH 9.96, s, H-7'; 10.14, s, H-8'), and two hydroxy protons 
(δH 13.43, s, OH-3'; 13.82, s, H-5'). Besides the characteristic signals for a diformylated 
phloroglucinol (DFPG) scaffold (δC 103.1, C-6'; 104.2 × 2, C-2'/C-4'; 163.5, C-1'; 168.0, C-3'; 
171.2, C-5'; 191.8, C-8'; 192.3, C-7'), 13C NMR spectral data (Table 1) showed 
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Table 1  
13C and 1H NMR data for eucalyprobusals A–E (1–5) in CDCl3 
 Eucalyprobusal A (1)a  Eucalyprobusal B (2)a  Eucalyprobusal C (3)b  Eucalyprobusal D (4)a  Eucalyprobusal E (5)a 
no. δC δH (J in Hz) δC δH (J in Hz) δC δH (J in Hz) δC δH (J in Hz) δC δH (J in Hz) 
1 76.5   75.9   72.7   82.4   76.3  
2 132.6 5.88 d (9.8) 133.4 5.79 d (10.0) 80.2 4.49 d (5.3) 195.5  150.0 6.81 d (10.1) 
3 135.9 5.83 dd (9.8, 1.0) 135.3 5.83 d (10.0) 111.6 5.10 d (5.3) 121.9 5.85 s 130.6 6.05 d (10.1) 
4 72.8  72.6  155.2  168.7  196.9  
5α 27.0 1.54 dd (13.4, 2.4) 35.4 1.51 brd (13.2) 32.4 2.62 dd (18.8, 6.3) 32.9 2.73 ddd (19.4, 5.6) 40.4 2.64 dd (20.1, 7.5) 
5β  1.38 t (13.4)  1.41 dd (13.2, 2.5)  1.86 brd (18.8)  2.46 brd (3.7)  2.52 t (7.5) 
6 33.1 2.26 ddd (13.4, 6.2, 3.0) 33.5 2.36 brdd (13.2, 3.2) 40.2 2.23 brt (4.8) 44.0 2.49 m 35.0 2.54 m 
7 23.7 1.39 s 27.2 1.55 s 26.4 1.65 s 22.5 1.63 s 25.4 1.67 s 
8 37.8 1.76 sept (6.8) 37.6 1.71 sept (6.8) 34.5 2.06 sept. (6.8) 35.6 2.43 sept. (6.8)   
9 16.2 0.93 d (6.8) 16.2 0.92 d (6.8) 21.1 0.74 d (6.8) 20.5 1.13 d (6.8)   
10 17.3 0.87 d (6.8) 17.3 0.83 d (6.8) 20.9 0.72 d (6.8) 20.7 1.12 d (6.8)   
1' 163.5  161.6  165.0  163.9  171.7  
2' 104.2  104.0  109.1  104.6  99.3  
3' 168.0  168.1  167.3  167.6  160.3  
4' 104.2  104.1  105.6  104.8  103.7  
5' 171.2  170.1  169.1  169.1  168.1  
6' 103.1  103.8  117.4  106.2  103.6  
7'a 192.3 9.96 s 192.3 9.99 s 193.7 10.10 s 192.6 10.14 s 21.5 2.41 dd (16.9, 6.0) 
7'b          2.81 dd (16.9, 6.0) 
8' 191.8 10.14 s 191.7 10.16 s 192.3 10.21 s 192.2 10.15 s 191.4 10.04 s 
9' 28.4 3.21 ddd (10.9, 6.2, 3.9) 34.0 2.64 brdd (10.2, 3.2) 35.9 3.52 dt (8.2, 4.9) 31.2 2.66 ddd (9.8, 6.3, 3.5) 206.6  
10'a 35.7 2.52 ddd (14.5, 10.9, 3.9) 43.3 1.80 ddd (13.1, 10.2, 3.2) 46.7 1.42 brdd (13.5, 6.8) 43.6 1.61 2H m 52.7 2.98 2H d (6.7) 
10'b  1.26 ddd (14.2, 10.9, 3.9)  1.58 ddd (14.2, 10.2, 3.2)  1.27 brdd (13.5, 7.7)     
11' 24.5 1.75 m 26.6 1.87 m 25.6 1.47 m 25.6 1.67 m 27.5 1.92 m 
12' 20.9 1.00 d (6.5) 21.6 1.01 d (6.5) 22.3 0.93 d (6.3) 22.2 0.97 d (6.4) 22.7 0.98 d (6.7) 
13' 24.3 0.96 d (6.5) 23.6 0.96 d (6.5) 22.8 0.85 d (6.3) 24.0 0.85 d (6.4)  22.7 0.98 d (6.7) 
OH-3'  13.43 s  13.44 s  13.29 s  13.35 s OH-1' 15.48 s 
OH-5'  13.82 s  13.48 s  13.31 s  13.38 s OH-5' 14.45 s 
aData were recorded at 500 MHz.  




Fig. 2. Selected 1H–1H COSY (blue bold line) and HMBC (red arrow) correlations of 1–11. 
23 carbon resonances ascribed to five methyls (δC 16.2, C-9; 17.3, C-10; 20.9, C-12'; 23.7, C-7; 
24.3, C-13'), two methylenes (δC 27.0, C-5; 35.7, C-10'), four methines (δC 24.5, C-11'; 28.4, C-
9'; 33.1, C-6; 37.8, C-8), an endocyclic double bond (δC 132.6, C-2; 135.9, C-3), and two oxygen-
bearing quaternary carbons (δC 72.8, C-4; 76.5, C-1). The aforementioned NMR signals of 1 
closely resembled those of eucalyptin D [6] recently obtained from E. globulus fruits, the 
difference being the configuration of the C-4 hydroxy group. Combined with three spin systems 
(Fig. 2) as furnished by the 1H−1H COSY experiment, HMBC correlations from H3-7 (δH 1.39) to 
C-6 (δC 33.4)/C-1 (δC 76.5)/C-2 (δC 132.6), from H3-10 (δH 0.89)/H3-9 (δH 0.93)/H2-5 (δH 1.54, 
1.38)/H-2 (δH 5.88) to C-4 (δC 72.8), from OH-3' (δH 13.43) to C-2' (δC 104.2)/C-4' (δC 104.2)/C-
3' (δC 168.0), from OH-5' (δH 13.82) to C-6' (δC 103.1)/C-4' (δC 104.2)/C-5' (δC 171.2), from H-7' 
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(δH 9.96) to C-2' (δC 104.2), from H-8' (δH 10.14) to C-4' (δC 104.2), and from H-9' (δH 3.21) to C-
6' (δC 103.1)/C-1' (δC 163.5) indicated that 1 was a phloroglucinol-monoterpene conjugate. 
Although the observed ROESY correlations of both H-6 (δH 2.26) and H-9' (δH 3.21) with H3-7 
(δH 1.39) (Fig. S1, Supporting Information) revealed that these protons occupied the same side of 
the molecule and were stochastically assigned as β-oriented, no available ROESY evidence was 
used to establish the configuration of the C-4 hydroxy group. However, needlelike crystals of 1 
were obtained from a mixed solution of acetone and methanol (1:1, v/v). Single-crystal X-ray 
diffraction analysis with Cu Kα radiation (Fig. 3) of 1 not only resolved the configuration of C-4 
hydroxyl, but also unequivocally established its absolute configuration (1R,4R,6R,9'S). 
 
Fig. 3. ORTEP drawing of 1. 
 
Eucalyprobusal B (2) was assigned to have the same molecular formula (C23H30O6) according 
to its HRESIMS ion at m/z 425.1942 [M + Na]+ (calcd for C20H30O6Na, 425.1935). The 1D NMR 
data (Table 1) of 2 were highly similar to those of 1, and they shared the same planar architecture 
(Fig. 2) after analysis of the 1H–1H COSY, HMBC, and HSQC data. Examination of the NMR 
data revealed that C-9', C-10', and C-11' were significantly deshielded by ΔδC +5.6, +7.6, and +2.1, 
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respectively, indicating that 2 should be a C-9' epimer of 1. This assumption was supported by the 
ROESY correlations (Fig. S1, Supporting Information) of both H-10'a (δH 1.80) and H-6 (δH 2.36) 
with H3-7 (δH 1.55). The absolute configuration (1R,4R,6R,9'R) of 2 was substantiated by a 
comparison of its calculated and experimental ECD spectra (Fig. 4). 
 
Fig. 4. Calculated and experimental ECD spectra for 2. 
 
Eucalyprobusal C (3) was determined to have the same molecular formula (C20H30O6) as 
those of 1 and 2 based on its HRESIMS ion at m/z 401.1978 [M – H]– (calcd for C20H29O6, 
401.1970). Inspection of the 1H and 13C NMR data of 3 (Table 1) suggested that it was also an 
adduct of a monoterpene and phloroglucinol moiety, of which the former unit is similar to that of 
euglobal G6 [26]. The 1H–1HCOSY spectrum (Fig. 1) revealed the presence of three structural 
fragments, H-2–H-3, H3-9–H-8–H3-10, and H2-5–H-6–H-9'–H2-10'–H-11'–H3-12' (H3-13'), for 
the monoterpene scaffold. In the HMBC spectrum, the observed correlations from H3-7 (δH 1.68) 
to C-6 (δC 40.2)/C-1 (δC 72.7)/C-2 (δC 80.2), from H2-5 (δH 2.62, 1.86) to C-3 (δC 111.6)/C-4 (δC 
155.2), and from H3-10 (δH 0.72)/Me-9 (δH 0.74) to C-4 validated the existence of a γ-terpinene 
derivative with a C-2 hydroxy group in 3. Compared with the remarkably different 13C NMR data 
for 1 and 2, the downfield chemical shifts of C-9 (δC 35.9) and C-10 (δC 46.7) indicated an α-
oriented configuration for the H-9 in 3. The ROESY correlations (Fig. S1, Supporting Information) 
of H-10'a (δH 1.42)/H-6 (δH 2.23)/H-2 (δH 4.49) with H3-7 (δH 1.65) proved that these protons were 
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all β-oriented. The experimental ECD spectrum with two positive Cotton effects at 221 (+27.39) 
and 290 (+2.04) nm as well as two negative Cotton effects at 267 (−1.44) and 343 (−4.56) nm (Fig. 
5) of 3 defined its absolute configuration (1S,2R,6R,9'R). 
 
Fig. 5. Calculated and experimental ECD spectra for 3. 
 
Eucalyprobusal D (4) was shown to possess a molecular formula of C20H30O6 due to its 
observed HRESIMS ion at m/z 423.1772 [M + Na]+ (calcd for C23H28O6Na, 423.1778). The NMR 
data (Table 1) of 4 highly resembled those of 3, with the exception for the presence of ketone 
carbonyl group (δC 195.5, C-2) in 4, instead of an oxygenated methine (δC 80.2, C-2; δH 4.49, H-
2) in 3. This placement of the ketone carbonyl carbon at C-2 was proved by HMBC correlation 
from H3-7 (δH 1.63) to C-6 (δC 44.0)/C-1 (δC 82.4)/C-2 (δC 195.5). Similarly, Me-7 in 4 was 
assigned a β-orientation, and the observed ROESY correlations (Fig. S1, Supporting Information) 
of H3-7 with both H-10'a (δH 1.61) and H-6 (δH 2.49) revealed the β-orientations for the C-9' 
isopentyl group and H-6 (Fig. 1). The absolute configuration (1S,6R,9'R) of 4 was established by 




Fig. 6. Calculated and experimental ECD spectra for 4. 
 
Eucalyprobusal E (5) was proved to share a molecular formula of C20H22O6 owing to its 
HRESIMS ion at m/z 397.1051 [M + K]+ (calcd for C20H22O6K, 397.1048). Its NMR data (Table 
1) were highly similar to those of euglobal IIc [27], except for the presence of a ketone carbon (δC 
196.9, C-4) and the disappearance of signals for the C-4 isopropyl functionality. Together with 
two fragments of H-2–H-3 and H2-5–H-6 revealed by the 
1H–1H COSY spectrum, HMBC 
correlations from H3-7 (δH 1.67) to C-6 (δC 35.0)/C-1 (δC 76.3)/C-2 (δC 150.0) and from both H-2 
(δH 6.81) and H2-5 (δH 2.64, 2.52) to C-4 (δC 196.9) indicated the existence of an α-phellandrene 
derivative with the loss of a C-4 isopropyl group (Fig. 1). In the ROESY spectrum, the key 
correlations of H3-7 (δH 1.67) with H-6 (δH 2.54) suggested that they shared a β-configuration. The 
experimental ECD curve with three positive Cotton effects at 215 (+2.07), 263 (+1.27), and 354 
(+0.03) nm as well as two negative Cotton effects at 239 (–0.61) and 292 (–0.58) nm (Fig. 7) 
defined the absolute configuration (1S,6S) of 5. 
 
Fig. 7. Calculated and experimental ECD spectra for 5. 
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Eucalyprobusal F (6) had a molecular formula of C23H28O5 as deduced from its HRESIMS 
ion at m/z 383.1872 [M – H]– (calcd for C20H27O5, 383.1864). The 
1H NMR spectrum displayed 
resonances for four secondary methyls (δH 0.88, d, J = 6.6 Hz, H3-13'; 0.94, d, J = 6.6 Hz, H3-12'; 
1.17 × 2, both d, J = 7.0 Hz, H3-8/H3-9), a tertiary methyl (δH 2.22, s, H3-10), three aromatic 
protons (δH 6.85, dd, J = 7.8, 1.5 Hz, H-4; 6.91, d, J = 7.8 Hz, H-5; 7.45, d, J = 1.5 Hz, H-2), and 
two aldehyde protons (δH 10.05 × 2, s, H-7'/H-8'). Apart from the readily discernable signals 
attributable for a diformylated phloroglucinol unit (δC 106.3 × 2, C-2'/C-4'; 111.3, C-6''; 169.1, C-
3'; 169.9 × 2, C-1'/C-5'; 193.1× 2, C-7'/C-8'), the 13C NMR data indicated the occurrence of five 
methyls (δC 19.5, C-10; 22.9, C-12'; 23.8, C-13'; 24.6, C-8; 24.7, C-9], one methylene (δC 42.9, C-
10'), three methines (δC 27.4, C-11'; 35.0, C-9'; 35.2, C-7), and a trisubstituted benzene ring (δC 
124.6, C-4; 127.7, C-2; 131.0, C-5; 134.7, C-6; 142.9, C-1; 146.8, C-3). Along with two spin 
systems in the 1H–1H COSY spectrum (Fig. 1), the HMBC correlations from H-4 (δH 6.85) to C-2 
(δC 127.7)/C-6 (δC 134.7), from H-5 (δH 6.91) to C-1 (δC 142.9)/C-3 (δC 146.8), from H3-8/H3-9 
(δH both 1.17) to C-3 (δC 146.8), and from H3-10 (δH 2.22) to C-5 (δC 131.0)/C-6 (δC 134.7)/C-1 
(δC 142.9) allowed the establishment of the monoterpene moiety as p-cymene.
7 The linkage of 
monoterpene and phloroglucinol units via a C-1–C-9′ bond was determined by the key HMBC 
correlations (Fig. 1) from H-9′ to C-2 (δC 127.7)/C-6 (δC 134.7)/C-1 (δC 142.9)/C-6' (δC 111.3)/C-
1' (δC 169.9)/C-5' (δC 169.9). Meroterpenoid 6 was determined to be a racemic mixture by HPLC 
analysis using a CHIRALPAK IC column (Fig. S2, Supporting Information). Chiral separation 
followed by ECD calculations determined the absolute configurations (9'S) and (9'R) for (+)-6 and 




Fig. 8. Calculated and experimental ECD spectra of (±)-6. 
Eucalyprobusone B (7) possessed a molecular formula of C12H14O5 as revealed by an 
HRESIMS ion at m/z 261.0735 [M + Na]+ (calcd for C12H14O5Na, 261.0733). With the assistance 
of HSQC, the 1H and 13C NMR data showed the characteristic resonances for an isopropenyl (δH 
1.16 × 2, d, J = 6.8 Hz, H3-10/H3-11; δC 19.1 × 2, H3-10/ H3-11; δH 3.68, sept., J = 6.8 Hz, H-9; δC 
99.6, C-9), one methoxy group (δH 3.68, s, OMe-9; δC 56.2, OMe-9), one pentasubstituted aromatic 
ring (δH 5.91, s, H-4; δC 90.8, CH-4; δC 103.4, C-2; δC 105.3, C-6; δC 168.1, C-3; δC 169.9, C-5; 
δC 171.8, C-1), an aldehyde group (δH 10.20, s, H-8; δC 192.7, CH-8), a ketone carbonyl (δC 210.5, 
C-7), and two hydroxy protons (δH 12.99, s, OH-5; δH 15.50, s, OH-1). The aforementioned data 
indicated that 7 was a monomeric formylated phloroglucinol similar to 1,5-dihydroxy-2-(2'-
methylpropionyl)-3-methoxy-6-methylbenzene [28], except for the replacement of a C-8 methyl 
(δH 1.97, s; δC 7.4) in the former by a formyl group (δH 10.20, s; δC 192.7) in 7. The HMBC 
correlations (Figure 1) from H3-10 (δH 1.16)/H3-11 (δH 1.16) to C-7 (δC 210.5), from OMe-3 (δC 
168.1), from H-8 (δH 10.20) to C-6 (δC 105.3), from OH-5 (δH 12.99) to C-4 (δC 90.8)/C-5 (δC 
169.9), and from OH-1 (δH 15.50) to C-2 (δC 103.4)/C-6 (δC 105.3)/C-1 (δC 171.8) established the 
structure of 7. 
Eucalyprobusone C (8) was deduced to have a molecular formula of C28H38O8 by its 
HRESIMS ion at m/z 503.2645 [M + H]+ (calcd for C28H39O8, 503.2639). The 1D NMR spectral 
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data of 8 (Table 2) indicated it was a dimeric resorcinol analogue. Similar to 7, the discernable 
signals for an isopropenyl (δH 1.12, d, J = 6.7 Hz, H3-10; δH 1.13, d, J = 6.7 Hz, H3-9; δH 3.82, 
sept., J = 6.7 Hz, H-8), an isobutyl (δH 1.11 × 2, d, J = 6.7 Hz, H3-10'/ H3-11'; 1.79 and 1.35, both 
m, H2-8'; 3.69, sext., J = 6.7 Hz, H-9'), an isopentyl (δH 0.88 × 2, d, J = 6.5 Hz, H3-4''/H3-5''; 1.44, 
brsept., J = 6.5 Hz, H-3''; 2.08, 2H, m, H2-2''; 5.01, t, J = 8.1 Hz, H-1''), two methoxyl groups (δH 
3.89, s, OMe-3'; 3.90, s, OMe-3), two aromatic protons (δH 6.10 × 2, s H-4/H-4'), and  
Table 2 
1H and 13C NMR Data for Eucalyprobusones C (8) and D (9) 
 Eucalyprobusone C (8)a  Eucalyprobusone D (9)b 
no. δC δH (J in Hz) δC δH (J in Hz) 
1 165.8   163.6  
2 104.6  104.0  
3 162.5  162.0  
4 93.6 6.10 s 92.8 6.07 s 
5 164.4  162.8  
6 110.3  106.0  
7 211.3  211.1  
8 39.9 3.82 sept. (6.7) 39.3  3.79 sept. (6.8) 
9 19.6 1.13 d (6.7) 19.2 1.17 d (6.8) 
10 19.7 1.12 d (6.7) 19.2 1.17 d (6.8) 
1' 165.8  169.9  
2' 104.6  105.6  
3' 162.5  165.3  
4' 93.6 6.10 s 104.8  
5' 164.4  168.4  
6' 110.3  103.5  
7' 211.6  15.1 3.74 2H s 
8' 27.8 a 1.79 m, b 1.35 m 193.2 10.15 s 
9' 46.7 3.69 sext. (6.7) 207.2  
10' 16.8 1.11 d (6.7) 52.2 3.00 2H d (6.7) 
11' 16.9 1.11 d (6.7) 25.2 2.44 brsept. (6.7) 
12'   22.7 0.99 d (6.7) 
13'   22.7 0.99 d (6.7) 
1'' 28.2 5.01 t (8.1)   
2'' 40.8 2.08 2H m   
3'' 27.4 1.44 brsept. (6.5)   
4'' 22.8 0.88 d (6.5)   
5'' 22.8 0.88 d (6.5)   
OH-1  9.50 s  16.76 s 
OH-1'  9.50 s  17.23 s 
OH-3'    10.31 s 
OH-5     8.93 s 
OH-5'     14.48 s 
OMe-3 56.2 3.90 s  55.8 3.86 s 
OMe-3' 56.2 3.89 s    
aData were recorded at 600 MHz in acetone-d6.  
bData were recorded at 500 MHz in CDCl3. 
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two hydroxy protons (δH 9.50 × 2, s, OH-1/OH-1') were readily recognized in the 
1H NMR 
spectrum (Table 2). Together with three fragments in blue bold lines (Fig. 1) as revealed by the 
1H–1H COSY spectrum, HMBC correlations from both H3-10 (δH 1.12) and H3-9 (δH 1.13) to C-7 
(δC 211.3), from H-9' (δH 3.69) to C-7' (δC 211.6), from OMe-3' (δH 3.89) to C-3' (δC 162.5), from 
OMe-3 (δH 3.90) to C-3 (δC 162.5), from both H-4 (δH 6.10) and H-4' (δH 6.10) to C-2 (δC 104.6)/C-
2' (δC 104.6)/C-6 (δC 110.3)/C-6' (δC 110.3)/C-3 (δC 162.5)/C-3' (δC 162.5)/C-5 (δC 164.4)/C-5' (δC 
164.4), and from H-1'' (δH 5.01) to C-6 (δC 110.3)/C-6' (δC 110.3)/C-3 (δC 162.5)/C-3' (δC 162.5)/C-
5 (δC 164.4)/C-5' (δC 164.4)/C-1 (δC 165.8)/C-1' (δC 165.8) not only verified that two methoxy 
resorcinol units were connected via a C-6–C-1''–C-6' bond. An HPLC analysis equipped with a 
CHIRALPAK IC column (Fig. S2, Supporting Information) indicated that 8 was a racemic 
mixture, and ECD calculations (Fig. 9) was used to establish the absolute configurations (1''S) and 
(1''R) for (+)-8 and (–)-8, respectively. 
 
Fig. 9. Calculated and experimental ECD spectra of (±)-8. 
 
Eucalyprobusone D (9) possessed a molecular formula of C24H28O9 as inferred from an 
HRESIMS ion at m/z 499.1345 [M + K]+ (calcd for C24H28O9K, 499.1365). The 
1H–1H COSY 
spectrum (Fig. 1) indicated two coupled systems of H3-9–H-8–H3-10 and H2-10'–H-11'–H3-
12'(H3-13'). In the HMBC spectrum (Fig. 1), correlations from H3-9/H3-10 (both δH 1.17) to C-7 
(δC 211.1), from OCH3-3 (δH 3.86)/H-4 (δH 6.07) to C-3 (δC 162.0), from OH-1 (δH 17.67) to C-1 
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(δC 163.6)/C-2 (δC 104.0)/C-6 (δC 106.0), and from OH-5 (δH 8.93) to C-4 (δC 92.8)/C-6 (δC 106.0) 
revealed the occurrence of an isobutyryl methoxy resorcinol moiety, whereas the observed 
correlations from H2-10' (δH 3.00 ) to C-9 (δC 207.2), from H-8' to C-3' (δC 165.3)/C-5' (δC 168.4), 
from OH-5' (δH 14.48) to C-6' (δC 103.5)/C-6' (δC 104.8), and from OH-1' (δH 17.23) to C-6' (δC 
103.5)/C-2' (δC 105.6) allowed the establishment of a mono-formylated isovaleryl phloroglucinol 
unit. The key HMBC correlations from H2-7' (δH 3.74) to C-5 (δC 162.8)/C-1 (δC 163.6)/C-3' (δC 
165.3)/C-1' (δC 169.9) unequivocally revealed that the two mono-phloroglucinol derivatives were 
connected by a C-7'–C-6 bond. 
Eucalyprobusones E (10) and F (11) were isolated as two pairs of enantiomers with the same 
molecular formula (C28H38O8) as that of 9 by HRESIMS (m/z 525.2467 [M + Na]
+, calcd for 
C28H38O8Na, 525.2459). A comparison of the 1D NMR data (Table 3) with those of 9 revealed 
that the isovaleryl in the latter was replaced by a sec-isovaleryl in the former ones. This was 
confirmed by the HMBC correlations from H3-9' (δH 1.10, J = 6.7 Hz for 10; 1.14, J = 6.7 Hz for 
11) to C-8' (δC 46.2 for both 10 and 11)/C-7' (δC 210.2 for 10, 210.0 for 11), and from Me-11' (δH 
0.80, t, J = 6.7 Hz for 10; 0.84, t, J = 6.7 Hz for 11) to C-10' (δC 27.3 for 10, 27.4 for 11)/C-8' (δC 
46.2 for both 10 and 11). Fortunately, a triclinic crystal obtained from a mixed solvent of acetone-
MeOH (1:1, v/v) of 10 and 11 was selected for X-ray diffraction study. The results indicated that 
C-7' sec-isobutyl and C-1'' isobutyl units were both unordered, suggesting the occurrence of two 
pairs of enantiomers (Fig. 10). Nevertheless, it was not feasible to obtain (+)-10, (‒)-10, (+)-11, 
and (‒)-11 by a chiral column after several attempts (Fig. S2, Supporting Information). Taking the 
relationships between the specific rotation values and absolute configurations of (+)-8 and (‒)-8 
into consideration, the absolute configurations of (+)-10, (‒)-10, (+)-11, and (‒)-11 could be 
provisionally assigned as (8'R,1''S), (8'R,1''R), (8'S,1''S), and (8'S,1''R), respectively, owing to the 
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fact that the existence of the C-7' sec-isobutyl could not strikingly affect the holistic absolute 
configurations that were determined by the specific rotation values [29]. 
Table 3 
13C (150 MHz) and 1H (600 MHz) NMR data for eucalyprobusones E (10) and F (11) in pyridine-d5 
 Eucalyprobusone E (10)   Eucalyprobusone F (11)  
no. δC δH (J in Hz) δC δH (J in Hz) 
1 166.6   165.6  
2 104.6  105.1  
3 161.4  161.5  
4 92.6 6.27 s 92.6 6.28 s 
5 164.4  164.5  
6 111.1  111.1  
7 210.0  210.2  
8 39.5 3.75 sept. (6.7) 39.5 3.75 sept. (6.7) 
9 19.4 1.13 d (6.7) 19.4 1.13 d (6.7) 
10 19.5 1.10 d (6.7) 19.5 1.10 d (6.7) 
1' 166.6  165.6  
2' 104.6  105.1  
3' 161.4  161.5  
4' 92.6 6.28 s 92.6 6.28 s 
5' 164.4  164.5  
6' 111.1  111.1  
7' 210.2  210.0  
8' 46.2 3.65 m 46.2 3.65 m 
9' 16.6 1.10 d (6.7) 16.7 1.14 d (6.7) 
10'a 27.3 1.80 m 27.4 1.82 m 
10'b  1.32 m  1.34 m 
11' 12.0 0.80 t (7.4) 12.1 0.84 t (7.4) 
1'' 27.9 6.03 t (8.3) 27.9 6.03 t (8.3) 
2'' 41.8 2.47 2H t (7.5) 41.8 2.47 2H t (7.5) 
3'' 26.9 1.92, br sept. (6.6) 26.9 1.92 br sept. (6.6) 
4'' 22.8 0.90 d (6.6) 23.0 1.09 d (6.6) 
5'' 23.0 1.08 d (6.6) 23.0 1.09 d (6.5) 
OMe-3/3' 55.3 3.64 s 55.3 3.65 s 
 
Fig. 10. ORTEP drawing of (±)-10 and (±)-11. 




AChE inhibitory effects of acylphloroglucinols 1–11 
compound IC50 ± SD (μM) compound IC50 ± SD (μM) 
1 > 40.0 7 > 40.0 
2 > 40.0 8 3.82 ± 0.22 
3 > 40.0 (+)-8 4.96 ± 0.68 
4 > 40.0 (–)-8 6.02 ± 0.54 
5 > 40.0 9 36.22 ± 2.29 
6 3.22 ± 0.36 10+11 2.55 ± 0.28 
(+)-6 4.79 ± 0.57   
(–)-6 5.85 ± 0.76 Galantaminea 1.05 ± 0.06 
aPositive drug. 
 
Given the PE–EtOAc extract of E. robusta fruits was AChE inhibitory (500 μg/mL, 68%), all 
the isolated acylphloroglucinols were screened for AChE inhibitory effects. At a concentration of 
40.0 μM, only acylphloroglucinols 6 and 8‒11 showed AChE inhibitory activities with inhibition 
rates ranging from 93.02 ± 0.71 to 71.97 ± 2.20 %. Further studies indicated these compounds 
were AChE inhibitory with IC50 values ranging from 2.55 ± 0.28 to 36.22 ± 2.29 μM, with the 
mixture of 10 and 11 being the most effective possessing an IC50 value of 2.55 ± 0.28 μM (Table 
4). Taking their structural characteristics and AChE inhibitory data into consideration, the 
observable structure–activity relationships can be summarized as follows (i) both FPMs featuring 
with a dihydropyran ring and acylphloroglucinol monomer were inactive; (ii) acylphloroglucinol 
dimers that be connected via an isopentyl moiety showed stronger AChE inhibitory effects than 
that of being linked by C-7'; (iii) the mixtures of (+)-6 /(–)-6 and (+)-8/(–)-8 showed stronger 
AChE inhibitory activities than (+)-6, (–)-6, (+)-8, or (–)-8. Compared with structurally diverse 
acylphloroglucinol-like compounds reported from various plants [30‒34], acylphloroglucinols 6, 
8, and the mixture of 10 and 11 isolated from E. robusta fruits displayed more potential AChE 
inhibitory effects. With regard to acylphloroglucinol derivatives obtained from species of 
Myrtaceae, apart from polymethylated phloroglucinol meroterpenoids (PPMs) isolated from 
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Rhodomyrtus tomentosa [35], the current findings indicated that FPM and acylphloroglucinol 
heterodimers [10] connected only by an isopentyl unit are more likely to be AChE inhibitors.  
3.3. Molecular docking investigation 
Considering acylphloroglucinols 6, 8, and the mixture of 10 and 11 displayed good AChE 
inhibitory properties, molecular modeling investigations were used to better understand their 
mechanism of action and the binding modes with AChE (Fig. 11). The results revealed that all 
these isolates may be buried into the hydrophobic pocket of AChE. More specifically, (i) the 
acylphloroglucinol unit of 6 appears to form hydrogen bonds with the Tyr337, Tyr341, Thr83, and 
Ser125 residues, the phenyl ring of the monoterpene moiety was bound to the Trp86 residue via 
the π−π stacking interactions, and the terminal methyl fragments of the isopentyl moiety formed 
π-σ stacking interactions with Phe297 and Tyr124 residues; (ii) both the C-5 and C-5' hydroxy 
groups of 8 could form hydrogen bonds with only the Tyr124 residue and two phenyl rings showed 
π–π interactions with Tyr341 and Trp86 residues, respectively, and the terminal methyl fragments 
of isopentyl, isobutyl, and isopropyl showed π–σ stacking interactions with Tyr337, 
Trp286/Phe297, and Trp286/Tyr337 residues, respectively; (iii) the phloroglucinol unit of both 10 
and 11 formed hydrogen bonds with Ser125, Tyr124, Tyr133, Tyr337, and Asn87 residues, the 
phenyl rings bearing a sec-isovaleryl group displayed π–π interactions with Trp86 and Tyr341 
residues; (iv) the phenyl rings bearing a sec-isovaleryl group of 10 also showed π–π interaction 
with Tyr337; (v) the terminal methyl fragments of 10 exhibited π-σ stacking interactions with 
Phe295, Phe297, Tyr124, and Trp86 residues, whereas those of 11 displayed π-σ stacking 




Fig. 11. The binding modes of 6 (A), 8 (B), 10 (C), and 11 (D) with human AChE (PDB ID: 4M0F). Hydrogen 
bond interactions are depicted with red dashes, while π–π and π–σ stacking interactions are displayed with yellow 
and green dashes, respectively. 
racemic acylphloroglucinols 10 and 11 shared more interaction sites with AChE than 6 and 9 did, 
which were also consistent with the results of their AChE inhibitory assay. 
4. Conclusion 
In summary, the systematically phytochemical investigation of E. robusta fruits resulted in 
the isolation of 11 new acylphloroglucinols, including seven new formylated phloroglucinol-
monoterpene meroterpenoids (1–6), one monomeric acylphloroglucinol (7), and four dimeric 
28 
 
acylphloroglucinols (8–11). Although all attempts to separate the 10 and 11 mixture have failed, 
X-ray diffraction was critical for confirming their structures and configuration. Compounds 6, 8, 
and the mixture of 10 and 11 displayed significant AChE inhibitory effects, and the possible 
interaction sites of these four compounds with AChE were investigated by molecular docking, 
which could be recognized as lead compounds for treatment of Alzheimer's disease.  
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